SerImmune

company

About

SerImmune provides a view of how the body responds to pathogens and other environmental factors.

  • 11 - 50

Details

Last Funding Type
Series A
Last Funding Money Raised
$8M
Industries
Biotechnology,Commercial,Health Care,Information Technology,Medical
Founded date
Jan 1, 2014
Number Of Employee
11 - 50
Operating Status
Active

SerImmune is an immune intelligence company that provides a view of immunity and how the body responds to pathogens and other environmental factors in disease and health. The information the company provides fuels the development of new diagnostics, vaccines, and therapeutics. SerImmune’s Immune Information Technology reveals the many antigens that determine functional immune repertoires. The many distinct antibodies within a repertoire can be mapped to antigens from infections, allergens, microbiome organisms, autoimmune diseases, and cancers.

SerImmune was founded in 2014 and is headquartered in Goleta, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$8M
SerImmune has raised a total of $8M in funding over 2 rounds. Their latest funding was raised on Jun 21, 2017 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 21, 2017 Series A $8M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
SerImmune is funded by 1 investors. Merck are the most recent investors.
Investor Name Lead Investor Funding Round
Merck Series A